Modelled DT Structure
Method: homology modeling
Template PDB: 4LDS_A
Identity: 30.732%
Minimized Score: -782.893 kcal/mol
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0266 | ||||
| Gene Name | SLC2A8 | ||||
| Protein Name | Glucose transporter type 8 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: homology modeling Template PDB: 4LDS_A Identity: 30.732% Minimized Score: -782.893 kcal/mol Detail: Structure Info |
||||
| Synonyms | GLUT-8; GLUT8; GLUTX1; Glucose transporter type X1; SLC2A8; Solute carrier family 2, facilitated glucose transporter member 8 | ||||
| DT Family | Major Facilitator Superfamily (MFS) | ||||
| Sugar Porter (SP) Family | |||||
| Tissue Specificity | Highly expressed in testis, but not intesticular carcinoma. Lower amounts present in most other tissues. | ||||
| Function | This insulin-regulated transporter facilitates glucose transport and binds cytochalasin B in a glucose-inhibitable manner. Seems to be a dual-specific sugar transporter as it is inhibitable by fructose. | ||||
| Endogenous Substrate(s) | Glucose | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
2-Deoxyglucose
|
Phase 1/2 | Drug Info | Cancer | 2A00-2F9Z | [1] |
|
Endogenous Metabolites (EMs) Handled by This DT |
|||||
|
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 1 EMs in Total | ||||
| EM Name | PubChem CID | Detail | Experimental Material | Ref | |
| L-lactate | EM Info | Identified using GLUT8-attenuated mice | [2] | ||
|
Drug-DT Affinity Assessed by Cell Line |
|||||
|
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
| 2-Deoxyglucose | Phase 1/2 | Drug Info | Xenopus oocytes-GLUT8 | Km = 2000 microM | [1] |
| References | |||||
| 1 | Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128. | ||||
| 2 | GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. Int J Cancer. 2017 Nov 15;141(10):2131-2142. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.